BIORA THERAPEUTICS Announces Regulation FD Disclosure for 2023.
March 24, 2023
Trending News 🌥️
BIORA ($NASDAQ:BIOR) Therapeutics, Inc. has recently announced that it has filed a Regulation FD Disclosure with the Securities and Exchange Commission (SEC) for their 2023 fiscal year. This Regulation FD Disclosure is intended to provide investors and shareholders with information on the company’s results, financial condition, liquidity, prospects, and other material information. BIORA Therapeutics seeks to provide innovative treatments for unmet medical needs through drug development and personalized medicine. Their research focuses on the development of novel drug molecules to treat rare diseases, cancer, and autoimmune diseases. The company is also working towards exploring the potential of its drug candidates in the pharmaceutical industry. The Regulation FD Disclosure will provide investors with detailed information on the company’s financial results, activities, and outcomes. It will also include information on the company’s strategic objectives for the next fiscal year, including research and development initiatives.
Additionally, this disclosure will provide insight into the company’s liquidity, capitalization, risks, and opportunities. The Regulation FD Disclosure from BIORA Therapeutics is an important step in ensuring that its investors have access to sufficient and timely information. This disclosure will allow investors to make informed decisions about their investments in the company. Furthermore, it will help BIORA Therapeutics in its mission to develop treatments for unmet medical needs, as investors will be better informed of the company’s progress and prospects.
Price History
On Friday, BIORA THERAPEUTICS, Inc. issued a disclosure under Regulation FD for the year 2023. The stock opened at $2.6 and closed at $2.8, indicating a positive market reaction and an increase of 3.4% from its previous closing price of $2.7. This surge in share price may reflect investors’ confidence in the company’s planned strategies for the coming year. As BIORA THERAPEUTICS continues to develop and market its therapeutic solutions, the potential for further progress is clear. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biora Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.73 | -117.31 | -11773.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biora Therapeutics. More…
| Operations | Investing | Financing |
| -93.44 | -0.51 | 76.32 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biora Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 62.61 | 160.06 | -12.88 |
Key Ratios Snapshot
Some of the financial key ratios for Biora Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -78.6% | – | -8304.0% |
| FCF Margin | ROE | ROA |
| -12970.4% | 38.9% | -60.2% |
Analysis
At GoodWhale, we have conducted a thorough analysis of BIORA THERAPEUTICS’ wellbeing. Based on our Risk Rating assessment, we have found that BIORA THERAPEUTICS is a high risk investment, both in terms of financial and business aspects. Our analysis has revealed four risk warnings for BIORA THERAPEUTICS: one in the balance sheet, one in the cash flow statement, and two in non-financial and financial journals. If you want to learn more about these risk warnings, you can register on goodwhale.com to access more detailed information. More…
Peers
The competition in the field of cancer therapeutics is heating up, with Biora Therapeutics Inc taking on NuCana PLC, GT Biopharma Inc, and CytomX Therapeutics Inc. While each company has its own unique approach to cancer treatment, they are all striving to be the best in the field. May the best company win!
– NuCana PLC ($NASDAQ:NCNA)
NuCana PLC is a pharmaceutical company that focuses on the development and commercialization of cancer treatments. The company has a market capitalization of $52.2 million and a return on equity of -44.76%. NuCana PLC’s products are designed to improve the treatment of cancer by targeting the disease at the cellular level. The company’s products are in various stages of development, including clinical trials.
– GT Biopharma Inc ($NASDAQ:GTBP)
ACGT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapies for the treatment of cancer. The company’s lead product candidates are ACGT087, a monoclonal antibody targeting CD73, and ACGT141, a monoclonal antibody targeting CTLA-4. ACGT Biopharma Inc is headquartered in San Diego, California.
– CytomX Therapeutics Inc ($NASDAQ:CTMX)
CytomX Therapeutics Inc is a clinical-stage biopharmaceutical company developing a novel class of investigational antibody therapeutics based on its Probody platform. The Probody platform is designed to improve the therapeutic index of antibodies by targeting them to cancer cells while limiting exposure to healthy tissues. CytomX’s lead product candidate, CX-072, is an anti-CD166 Probody therapeutic antibody in Phase 1 clinical testing for the treatment of solid tumors.
Summary
BIORA Therapeutics, Inc. recently released a disclosure statement under the Regulation FD, providing investors with updates on their performance and plans for 2023. The news immediately caused investors to show keen interest in the stock, as the stock price moved up significantly on the same day. This could be a great opportunity for investors looking to gain exposure to a growing biotechnology company.
As BIORA’s plans become clearer, investors may want to take a closer look at the company’s financials and operations to determine the potential for growth and profitability. With a strong focus on research and development, BIORA looks capable of delivering strong returns to investors.
